Biogen CEO Michel Vounatsos on seeking FDA approval for new Alzheimer's drug

Biogen made a surprise reversal on its Alzheimer's treatment drug with plans to now seek regulatory approval. Biogen CEO Michel Vounatsos joins CNBC's "Squawk Box" team to discuss the change.
07:40
Wed, Oct 23 20198:35 AM EST